The EU regulatory class covering gene, tissue and cell-based medicines.
A regulatory classification (EU ATMP, advanced therapy medicinal product) for cell and gene therapies that require proof of quality, safety, and efficacy before approval. It's a gold-standard designation meaning the therapy has undergone rigorous manufacturing oversight and clinical testing. Clinics advertising "advanced therapy" products are working within regulated frameworks; clinics bypassing this classification are often operating in regulatory grey zones. Ask clinics whether their products hold ATMP designation or equivalent (FDA approval, etc.); if not, ask why and whether they're pursuing it. Lack of regulatory approval signals either early-stage research or intentional circumvention.
GMP-сертифицированная регенеративная медицина в сердце ЕС — от €3 000–8 000, доля от цен США или Германии. Индивидуальные протоколы для пациентов из 50+ стран.
Бесплатная оценка врача